Erasca (ERAS) Interest Coverage Ratio (2020 - 2025)
Erasca posted quarterly Interest Coverage Ratio of 470.68 for Q2 2025, down 219.42% year-on-year from 394.12 in Q2 2024, and little changed on a QoQ basis from 468.82 in Q1 2025.
Erasca (ERAS) has 6 years of Interest Coverage Ratio data on file, last reported at 470.68 in Q2 2025.
- For the quarter ending Q2 2025, Interest Coverage Ratio fell 219.42% year-over-year to 470.68; the trailing twelve-month figure through Mar 2026 stood at 3619.58 (down 1000.04% YoY), and the FY2025 full-year result was 568.17, down 582.1% from the prior year.
- Interest Coverage Ratio for Q2 2025 stood at 470.68, roughly flat from 468.82 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 147.35 in Q2 2024 and bottomed at 2761.56 in Q4 2022.
- The 5-year median for Interest Coverage Ratio is 544.85 (2022), against an average of 672.7.
- The widest annual swing landed in 2023, when Interest Coverage Ratio surged 81.69%; it then tumbled 219.42% in 2025.
- A 5-year view of Interest Coverage Ratio shows it stood at 622.22 in 2021, then sank by 343.83% to 2761.56 in 2022, then soared by 81.69% to 505.55 in 2023, then soared by 70.85% to 147.35 in 2024, then sank by 219.42% to 470.68 in 2025.
- The last three Interest Coverage Ratio figures came in at 470.68 (Q2 2025), 468.82 (Q1 2025), and 147.35 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -470.68 |
| Mar 31, 2025 | -468.82 |
| Jun 30, 2024 | -147.35 |
| Mar 31, 2024 | -588.65 |
| Dec 31, 2023 | -505.55 |
| Sep 30, 2023 | -707.31 |
| Jun 30, 2023 | -580.16 |
| Mar 31, 2023 | -725.98 |
| Dec 31, 2022 | -2,761.56 |
| Sep 30, 2022 | -754.33 |
| Jun 30, 2022 | -394.56 |
| Mar 31, 2022 | -544.85 |
| Sep 30, 2021 | -622.22 |
| Jun 30, 2021 | -462.03 |
| Mar 31, 2021 | -356.49 |
| Sep 30, 2020 | -293.76 |
| Jun 30, 2020 | -220.73 |